EUVIMEDDescoperă EUVIMED
Crossref

FDA reverses course, won't approve leucovorin for autism

The Brown University Psychopharmacology Update · 2026-05 · 37 (5) · 5-5

DOI: 10.1002/pu.31442 ↗

At a glance

Journal article in The Brown University Psychopharmacology Update, published online on 2026-04-08.

RezumatDate bibliograficeCiteRelated studies

Abstract (original language)

The Trump administration has changed direction from its prior intent to approve an indication for the folic acid derivative leucovorin that had raised serious concern in the research and legal communities (see April 2026 issue of the Update). The Food and Drug Administration (FDA) announced in March that it will not approve leucovorin for the treatment of some patients with autism. The FDA had announced at a September 2025 press conference that it intended to approve leucovorin, marketed as Wellcovorin, in autism treatment despite no evidence of benefit from any randomized controlled trial. Critics of the announcement pointed out that the FDA appeared to be basing its decision-making solely on evidence from case reports and mechanistic data — a much lower standard than the randomized trial evidence customarily required for drug approvals. Now the FDA says its scientific review has determined that there is not enough evidence to support the use of leucovorin to treat patients with autism. The agency is approving a new indication for the drug in treating cerebral folate deficiency in patients with a rare variant in the folate receptor 1 gene. In announcing this new indication, the FDA stated that the approval was based on a systematic review of published case reports and mechanistic data, with no data from clinical trials cited.

Cite

APA

(2026). FDA reverses course, won't approve leucovorin for autism. The Brown University Psychopharmacology Update, 37(5), 5-5. https://doi.org/10.1002/pu.31442

Vancouver

FDA reverses course, won't approve leucovorin for autism. The Brown University Psychopharmacology Update. 2026;37(5):5-5. doi:10.1002/pu.31442

BibTeX
@article{euvimed2026,
  title = {FDA reverses course, won't approve leucovorin for autism},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {5},
  pages = {5--5},
  doi = {10.1002/pu.31442}
}
Start for free →